EUVIMEDEUVIMED entdecken
Open Access

TNF‐like weak inducer of apoptosis inhibition is comparable to IL‐13 blockade in ameliorating atopic dermatitis inflammation

Rinkesh K Gupta, Jacqueline Miller, Michael Croft iD

Allergy · 2024

DOI: 10.1111/all.15879 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Allergy, 2024. Verfasst von Rinkesh K Gupta und 2 weiteren Autor:innen. Beteiligte Einrichtung: Center for Autoimmunity and Inflammation, La Jolla Institute for Immunology, La Jolla, California, USA. Hauptthemen laut MEDLINE: Interleukin-13, Dermatitis, Atopic. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAMS NIH HHS, NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Targeting IL‐13 is highly efficacious in patients with Th2‐biased atopic dermatitis (AD), but inhibition of other inflammatory molecules might also limit disease. We investigated the importance of the TNF family cytokine TNF‐like weak inducer of apoptosis (TWEAK; TNFSF12) to keratinocyte dysregulation and the pathogenesis of AD in mice and also tested if blocking TWEAK has a similar therapeutic effect as targeting IL‐13.

Methods

Conditional knockout mice lacking Fn14 (TNFRSF12A), the receptor for TWEAK, only in keratinocytes, were repetitively sensitized with house dust mite allergen and analyzed for AD‐like skin inflammation. To determine the translational potential, wild‐type mice with AD were therapeutically treated with anti‐TWEAK and/or anti‐IL‐13 antibodies, and skin inflammation was assessed.

Results

Mice deficient in Fn14 in keratinocytes were resistant to developing maximal clinical features of AD, exhibiting reduced epidermal hyperplasia and dermal thickening, less skin infiltration of immune cells, and downregulated inflammatory gene expression. Moreover, therapeutic neutralization of TWEAK in wild‐type mice with AD reduced all of the pathological features to a comparable extent as blocking IL‐13.

Conclusions

The activity of TWEAK in keratinocytes contributes to AD development, and neutralizing TWEAK represents a future potential therapeutic option in human AD similar to targeting IL‐13.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interleukin-13Dermatitis, AtopicHumansAnimalsMiceTWEAK ReceptorInflammationApoptosisMice, Knockout

Stichwörter der Autor:innen

TWEAKallergydermatitisinflammationskin

Substanzen

Interleukin-13TWEAK Receptor

Autor:innen und Institutionen

  • Center for Autoimmunity and Inflammation, La Jolla Institute for Immunology, La Jolla, California, USA.
  • Department of Medicine, University of California San Diego, La Jolla, California, USA.

ORCID-Profile: Michael Croft

Förderung

  • NIAMS NIH HHS
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Gupta, R. K., Miller, J., & Croft, M. (2024). TNF‐like weak inducer of apoptosis inhibition is comparable to IL‐13 blockade in ameliorating atopic dermatitis inflammation. Allergy. https://doi.org/10.1111/all.15879

Vancouver

Gupta RK, Miller J, Croft M. TNF‐like weak inducer of apoptosis inhibition is comparable to IL‐13 blockade in ameliorating atopic dermatitis inflammation. Allergy. 2024. doi:10.1111/all.15879

BibTeX
@article{Gupta2024,
  author = {Gupta, Rinkesh K and Miller, Jacqueline and Croft, Michael},
  title = {TNF‐like weak inducer of apoptosis inhibition is comparable to IL‐13 blockade in ameliorating atopic dermatitis inflammation},
  journal = {Allergy},
  year = {2024},
  doi = {10.1111/all.15879}
}
Kostenlos starten →